India's SII Could Resume Covishield Shot Production as COVID Cases Rise

India's SII Could Resume Covishield Shot Production as COVID Cases Rise

NEW DELHI (Reuters) - The Serum Institute of India (SII) could resume production of the Covishield COVID-19 vaccine, a company spokesperson said on Wednesday, as infections rise in the country.

The world's biggest vaccine maker already has a stock of 6 million doses of Covovax, a version of a Novavax vaccine, the spokesperson added. Covishield is a version of an AstraZeneca shot.

(Reporting by Sakshi Dayal; Editing by Krishna N. Das)

Source: MEDspace